ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

ClinicalTrials.gov ID: NCT04821622

Public ClinicalTrials.gov record NCT04821622. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 5, 2026, 12:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER

Study identification

NCT ID
NCT04821622
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer
Industry
Enrollment
599 participants

Conditions and interventions

Interventions

  • Placebo plus enzalutamide Drug
  • talazoparib plus enzalutamide Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 11, 2021
Primary completion
Feb 17, 2026
Completion
Aug 27, 2027
Last update posted
Apr 6, 2026

2021 – 2027

United States locations

U.S. sites
45
U.S. states
18
U.S. cities
29
Facility City State ZIP Site status
University of Alabama at Birmingham Birmingham Alabama 35233
University of Alabama at Birmingham Birmingham Alabama 35249
Arizona Institute of Urology, PLLC Tucson Arizona 85704
Beverly Hills Cancer Center Beverly Hills California 90211
Adventist Health Glendale Glendale California 91206
VA Long Beach Healthcare System Long Beach California 90822
Yale-New Haven Hospital New Haven Connecticut 06510
MedStar Georgetown University Hospital Washington D.C. District of Columbia 20007
Washington Cancer Institute at MedStar Washington Hospital Center Washington D.C. District of Columbia 20010
AdventHealth Medical Group Hematology and Oncology Orlando Florida 32804
Investigational Drug Services, Advent Health Orlando Orlando Florida 32804
Northwest Georgia Oncology Centers, a Service of WellStar Cobb Hospital Austell Georgia 30106
Wellstar Cobb Hospital Austell Georgia 30106
Northwest Georgia Oncology Centers, a Service of Tanner Medical Center Villa Rica Carrollton Georgia 30117
West Georgia Infusion Center, a Service of Tanner Medical Center Villa Rica Carrollton Georgia 30117
Northwest Georgia Oncology Centers, a Service of WellStar Cobb Hospital Cartersville Georgia 30121
Northwest Georgia Oncology Centers, a Service of WellStar Cobb Hospital Douglasville Georgia 30134
Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital Marietta Georgia 30060
Comprehensive Urologic Care, SC Lake Barrington Illinois 60010
Mid-Illinois Hematology & Oncology Associates, Ltd Normal Illinois 61761
Henry Ford Health System Detroit Michigan 48202
Henry Ford Medical Center - New Center One Detroit Michigan 48202
Revive Research Institute, Inc. Farmington Hills Michigan 48334
David C. Pratt Cancer Center St Louis Missouri 63141
New Jersey Cancer Care, P.A. Belleville New Jersey 07109
Premier Medical Group of the Hudson Valley PC Poughkeepsie New York 12603
Providence Cancer Institute Franz Clinic Portland Oregon 97213
Keystone Urology Specialists Lancaster Pennsylvania 17604
Carolina Urologic Research Center, LLC Myrtle Beach South Carolina 29572
Parkway Surgery Center Myrtle Beach South Carolina 29572
Bristol Regional Medical Center Bristol Tennessee 37620
Ballad Health Cancer Care - Kingsport Kingsport Tennessee 37660
Holston Valley Hospital and Medical Center Kingsport Tennessee 37660
Indian Path Community Hospital Kingsport Tennessee 37660
Kelsey Research Foundation Houston Texas 77005
Oncology Consultants, P.A. Houston Texas 77008
Kelsey-Seybold Clinic Houston Texas 77014
oncology Consultants, P.A. Houston Texas 77024
Kelsey-Seybold Clinic Houston Texas 77025
Houston Metro Urology Houston Texas 77027
Oncology Consultants P.A. Houston Texas 77030
Kelsey-Seybold Clinic Houston Texas 77055
Urology San Antonio San Antonio Texas 78229
Texas Oncology-Deke Slayton Cancer Center Webster Texas 77598
Huntsman Cancer Institute - University of Utah Salt Lake City Utah 84112

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 266 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04821622, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 6, 2026 · Synced May 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04821622 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →